NeonMind Developing Music Playlist for Psychedelic Therapy Sessions
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC PINK: NMDBF) ("NeonMind"), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions. Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience. Figure 1: NeonMi
2021-04-06 6:00 AM EDT
NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use of psychedelics in treating obesity and eating disorders.
2021-03-30 6:00 AM EDT
NeonMind CEO Provides Update on the Progress of its Psilocybin Drug Development Research Plan and Team
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) ("NeonMind"), provides an update from CEO Rob Tessarolo on its research and development activities, as well as its plan to further develop two of its synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder and as an aid to weight loss and its maintenance. NeonMi
2021-03-23 2:00 AM EDT
NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) ("NeonMind") is pleased to announce that on March 10, 2021 NeonMind engaged Certara®, the global leader in model-informed drug development to provide strategic integrated drug development support for the investigation of NeonMind's psilocybin based drug candidates for the treatment of obesity. Figure
2021-03-11 6:00 AM EST
NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) ("NeonMind") is pleased to announce that on March 4, 2020 NeonMind engaged Philippe Martin as a drug development consultant. Figure 1: NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity To view an enhanced version of Figure
2021-03-09 2:00 AM EST
NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
Vancouver, British Columbia--(Newsfile Corp. - March 2, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FSE: 6UF) ("NeonMind") is pleased to announce that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind's preclinical trial. NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
2021-03-02 6:00 AM EST
NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) ("NeonMind"), announces that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. ("Psygen") for its planned phase 2 human clinical trial expected to begin in Canada later this year. NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial
2021-02-24 3:01 AM EST
NeonMind Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight Stress
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), announces that through its consumer products division, it submitted on February 2, 2021 four applications to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD), to obtain product licenses for its products with 100% plant-based extracts, and make their related health claims.
2021-02-10 6:00 AM EST
NeonMind Appoints Robert Tessarolo as President and Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce the appointment of accomplished pharmaceutical executive Robert Tessarolo as its President and Chief Executive Officer. NeonMind Appoints Rob Tessarolo as President and CEO To view an enhanced version of this image, please visit:
2021-01-27 3:01 AM EST
NeonMind Lists on the Frankfurt Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (the "FSE") under the symbol "6FU". As a result, NeonMind's common shares are now cross-listed on the Canadian Securities Exchange and the FSE.
2021-01-19 2:00 AM EST
NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind") a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in selecting or developing music playlists for its clinical trials or for use with treatments to support optimum mental health.
2021-01-14 6:30 AM EST
NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of...
2021-01-12 6:30 AM EST
NeonMind Announces Grants Pursuant to Stock Option Plan
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), a psychedelic drug development company, granted a total of 5,940,000 incentive stock options. 250,000 were granted to directors, 4,900,000 were granted to officers and 790,000 were granted to consultants under the Company's incentive stock option plan (the "Plan"). The options are exercisable into common shares of the Company at a price of $0.25 per share and are subject to a...
2021-01-11 8:01 PM EST
NeonMind Appoints Trevor Millar as Chief Psychedelic Officer
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms and commercializing medicinal mushroom products, is pleased to announce that it has appointed Trevor Millar as Chief Psychedelic Officer of NeonMind as of January 6, 2021. NeonMind Appoints Trevor Millar as Chief Psy
2021-01-07 6:30 AM EST
NeonMind Commences Trading Under CSE Ticker Symbol "NEON"
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind") is pleased to announce that its common shares have today commenced trading on the Canadian Securities Exchange (the "Exchange") under the ticker symbol "NEON". More information on NeonMind can be found at www.neonmindbiosciences.com.
2021-01-04 6:00 AM EST
NeonMind Announces Closing of Oversubscribed Initial Public Offering and Exercise in Full of the Agent's Over-Allotment Option
Vancouver, British Columbia--(Newsfile Corp. - December 30, 2020) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), is pleased to announce that it has successfully completed the maximum offering for its initial public offering (the "IPO") of 46,000,000 units of NeonMind (the "Units") at a price to the public of $0.10 per Unit, including 6,000,000 in additional Units pursuant to the exercise in full of the over-allotment option. The gross proceeds from the IPO, before deducting agent fees...
2020-12-30 6:06 PM EST